# Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML

> **NCT03661515** · PHASE1 · COMPLETED · sponsor: **PETHEMA Foundation** · enrollment: 16 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Selinexor
- **DRUG:** fludarabine
- **DRUG:** idarubicin
- **DRUG:** cytarabine
- **DRUG:** G-CSF

## Key facts

- **NCT ID:** NCT03661515
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-17
- **Primary completion:** 2019-07-15
- **Final completion:** 2019-10-15
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2020-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03661515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03661515, "Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03661515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*